The role of polymorphism of interleukin-2, -10, -13 and TNF-? genes in cutaneous T-cell lymphoma pathogenesis.
Ontology highlight
ABSTRACT: INTRODUCTION:As the pathogenesis of cutaneous T-cell lymphomas (CTCL) is not fully understood, inherited gene polymorphisms are considered to play a role in the development of lymphomas. AIM:To investigate whether certain gene polymorphisms might be involved in the development of CTCL. MATERIAL AND METHODS:In the case-control study we compared the frequency of nine selected single nucleotide polymorphisms (SNP) of seven genes (rs1800587/-889 C/T of interleukin (IL)-1?, rs2069762/-330G/T) and rs2069763/+166G/T of IL-2, rs1800925/-1112 C/T of IL-13, rs1800896/-1082 A/G of IL-10, rs4073/-251 A/T of IL-8, rs5370/K198N, rs180054/-1370T/G of endothelin-1 and rs1800629/-308 G/A of TNF-?) in 43 CTCL and Polish cases using the amplification refractory mutation system polymerase chain reaction method. RESULTS:We have found that two genotypes, -330GG of IL-2 and -1112TT of IL-13 both promoter variants associated with "hypertranscription phenotype", were over-represented in CTCL patients compared to healthy controls, and they increase the risk of malignancy development (OR = 5.82, p = 0.001 for IL-2 -330 GG, and OR = 5.67, p = 0.0024 for IL-13 -1112 TT). On the other hand, high transcription -308A allele of the TNF-? gene and -1082GG of IL-10 genotype is less frequent in lymphoma patients and has protective effects on the development of CTCL (OR = 0.45, p = 0.0466 for -308A of TNF-?, and OR = 0.35, p = 0.0329 for -1082GG of IL-10 genes). CONCLUSIONS:Our results indicate that hypertranscription promoter variants of IL-2 and IL-13 genes could be estimated as the risk factor for development of CTCL, while TNF-? and IL-10 variants have a protective effect.
SUBMITTER: Nedoszytko B
PROVIDER: S-EPMC5183781 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA